Literature DB >> 17878335

Human effector memory CD4+ T cells directly recognize allogeneic endothelial cells in vitro and in vivo.

Stephen L Shiao1, Nancy C Kirkiles-Smith, Benjamin R Shepherd, Jennifer M McNiff, Edward J Carr, Jordan S Pober.   

Abstract

The frequency of circulating alloreactive human memory T cells correlates with allograft rejection. Memory T cells may be divided into effector memory (T(EM)) and central memory (T(CM)) cell subsets, but their specific roles in allograft rejection are unknown. We report that CD4+ T(EM) (CD45RO+ CCR7- CD62L-) can be adoptively transferred readily into C.B-17 SCID/bg mice and mediate the destruction of human endothelial cells (EC) in vascularized human skin grafts allogeneic to the T cell donor. In contrast, CD4+ T(CM) (CD45RO+ CCR7+ CD62L+) are inefficiently transferred and do not mediate EC injury. In vitro, CD4+ T(EM) secrete more IFN-gamma within 48 h in response to allogeneic ECs than do T(CM). In contrast, T(EM) and T(CM) secrete comparable amounts of IFN-gamma in response to allogeneic monocytes (Mo). In the same cultures, both T(EM) and T(CM) produce IL-2 and proliferate in response to IFN-gamma-treated allogeneic human EC or Mo, but T(CM) respond more vigorously in both assays. Blockade of LFA-3 strongly inhibits both IL-2 and IFN-gamma secretion by CD4+ T(EM) cultured with allogeneic EC but only minimally inhibits responses to allogeneic Mo. Blockade of CD80 and CD86 strongly inhibits IL-2 but not IFN-gamma production by in response to allogeneic EC or Mo. Transduction of EC to express B7-2 enhances allogeneic T(EM) production of IL-2 but not IFN-gamma. We conclude that human CD4+ T(EM) directly recognize and respond to allogeneic EC in vitro by secreting IFN-gamma and that this response depends on CD2 but not CD28. Consistent with EC activation of effector functions, human CD4+ T(EM) can mediate allogeneic EC injury in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878335     DOI: 10.4049/jimmunol.179.7.4397

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling.

Authors:  Jiasheng Zhang; Teresa Silva; Timur Yarovinsky; Thomas D Manes; Sina Tavakoli; Lei Nie; George Tellides; Jordan S Pober; Jeffrey R Bender; Mehran M Sadeghi
Journal:  Circ Res       Date:  2010-06-10       Impact factor: 17.367

2.  Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.

Authors:  Birgit Fogal; Tai Yi; Chen Wang; Deepak A Rao; Amir Lebastchi; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

3.  Identification of endothelial cell junctional proteins and lymphocyte receptors involved in transendothelial migration of human effector memory CD4+ T cells.

Authors:  Thomas D Manes; Jordan S Pober
Journal:  J Immunol       Date:  2010-12-29       Impact factor: 5.422

4.  An Endothelial Planar Cell Model for Imaging Immunological Synapse Dynamics.

Authors:  Roberta Martinelli; Christopher V Carman
Journal:  J Vis Exp       Date:  2015-12-24       Impact factor: 1.355

5.  Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions.

Authors:  Cécile Taflin; Benoit Favier; Jeremy Baudhuin; Alain Savenay; Patrice Hemon; Armand Bensussan; Dominique Charron; Denis Glotz; Nuala Mooney
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

6.  Antigen presentation by human microvascular endothelial cells triggers ICAM-1-dependent transendothelial protrusion by, and fractalkine-dependent transendothelial migration of, effector memory CD4+ T cells.

Authors:  Thomas D Manes; Jordan S Pober
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

7.  Transforming growth factor beta expression by human vascular cells inhibits interferon gamma production and arterial media injury by alloreactive memory T cells.

Authors:  A H Lebastchi; S F Khan; L Qin; W Li; J Zhou; N Hibino; T Yi; D A Rao; J S Pober; G Tellides
Journal:  Am J Transplant       Date:  2011-08-03       Impact factor: 8.086

8.  Long-term Nonhuman Primate Renal Allograft Survival Without Ongoing Immunosuppression in Recipients of Delayed Donor Bone Marrow Transplantation.

Authors:  Kiyohiko Hotta; Tetsu Oura; Abbas Dehnadi; Svjetlan Boskovic; Masatoshi Matsunami; Ivy Rosales; Rex N Smith; Robert B Colvin; A Benedict Cosimi; Tatsuo Kawai
Journal:  Transplantation       Date:  2018-04       Impact factor: 4.939

Review 9.  Inflammasomes and IL-1 biology in the pathogenesis of allograft dysfunction.

Authors:  S Samuel Weigt; Vyacheslav Palchevskiy; John A Belperio
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

10.  Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.

Authors:  Dan Jane-Wit; Thomas D Manes; Tai Yi; Lingfeng Qin; Pamela Clark; Nancy C Kirkiles-Smith; Parwiz Abrahimi; Julie Devalliere; Gilbert Moeckel; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  Circulation       Date:  2013-09-17       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.